Merck has extended its preventative and chronic disease care alliance with healthcare provider Premier to devise new solutions to minimise the recurrence of a Clostridium difficile (C. diff) infection.

Under the arrangement, the partners will develop and test a software platform and coordinator combination to offer surveillance, consultation, support and education to patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The project will cover volunteer Premier member health systems and aims to improve access to healthcare services, as well as provide awareness on reducing and detecting disease recurrence.

Merck Hospital/Specialty Marketing associate vice-president Raquel Tapia said: “Combining the technical capabilities of Premier and the therapeutic area expertise of Merck has been instrumental in our ability to address these difficult healthcare challenges.

“By testing the solutions in real-world settings and learning from our growing knowledge base, we’re confident that our work together will help patients.”

“By testing the solutions in real-world settings and learning from our growing knowledge base, we’re confident that our work together will help patients.”

Merck and Premier have been partnering since 2016 to create and test interventions to advance wellness and prevention in certain at-risk patient populations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Premier expects the latest collaboration to help in enhancing follow-up and management of the condition through increased clinician and patient knowledge.

Statistics indicate that C. diff infects approximately 500,000 people in the US, leading to an estimated $4.8bn in excess healthcare costs annually.

Even though the C. diff infection can be treated, one in five patients experiences a recurrence. Moreover, patients taking antibiotics are said to be more prone to this infection during and one month after therapy.